EntreMed   
EntreMed, Inc. 是一家致力于开发 ENMD-2076 的临床阶段制药公司。ENMD-2076 是用于治疗癌症的选择性血管生成激酶抑制剂。ENMD-2076 目前正在进行一项多中心二期卵巢癌研究，并且已经完成了多个有关实体肿瘤、多发性骨髓瘤和白血病的一期研究

EntreMed, Inc. is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global market. Its lead compound, ENMD-2076, a selective angiogenic kinase inhibitor, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer. EntreMed, Inc. recently initiated a Phase 2 study of ENMD-2076 in triple-negative breast cancer.